Cargando…
Fusogenic Viruses in Oncolytic Immunotherapy
Oncolytic viruses are under intense development and have earned their place among the novel class of cancer immunotherapeutics that are changing the face of cancer therapy. Their ability to specifically infect and efficiently kill tumor cells, while breaking immune tolerance and mediating immune res...
Autores principales: | Krabbe, Teresa, Altomonte, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070779/ https://www.ncbi.nlm.nih.gov/pubmed/29949934 http://dx.doi.org/10.3390/cancers10070216 |
Ejemplares similares
-
Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma
por: Krabbe, Teresa, et al.
Publicado: (2021) -
Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures
por: Göbel, Sven, et al.
Publicado: (2022) -
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy
por: Marek, Janina, et al.
Publicado: (2023) -
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017) -
Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy
por: Reale, Alberto, et al.
Publicado: (2021)